Necrobiosis Lipoidica Diabeticorum (2024)

  • Journal List
  • Case Rep Pediatr
  • v.2012; 2012
  • PMC3350198

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Necrobiosis Lipoidica Diabeticorum (1)

Case Reports in Pediatrics

Case Rep Pediatr. 2012; 2012: 152602.

Published online 2012 Apr 22. doi:10.1155/2012/152602

PMCID: PMC3350198

PMID: 22606526

Andrea Scaramuzza,1,* Maddalena Macedoni,1 Gian Luca Tadini,2 Laura De Angelis,1 Francesca Redaelli,1 Alessandra Gazzarri,1 Valentina Comaschi,1 Elisa Giani,1 and Gian Vincenzo Zuccotti1

Author information Article notes Copyright and License information PMC Disclaimer

Abstract

Necrobiosis lipoidica is a rare disorder that usually appears in the lower extremities and it is often related to diabetes mellitus. There are few reported cases of necrobiosis lipoidica in children. We present an interesting case in that the patient developed lesions on the abdomen, which is an unusual location.

1. Case Report

A 16-years-old girl, with type 1 diabetes diagnosed elsewhere in 2000, was brought to our Department for a first routine visit in 2006, during which two yellow-brown, atrophic plaques surrounded by raised, violaceus rims on the right side of the lower abdomen (0.79 × 0.2 in and 1.38 × 0.79 cm, resp.) (Figure 1) were observed. Several other plaques had been observed on both legs (Figure 2). No other significant finding had been seen. A careful history revealed that she was on bad terms with her diabetes. Since diagnosis she had a multiple daily injections (MDIs) scheme for her insulin therapy (mean insulin requirement: 0.97 U/kg/day). Due to poor glycemic control she was switched to insulin pump therapy in 2006. Despite a slight improvement in glycemic values and reduction in insulin requirement (0.70 U/kg/day), her glycated hemoglobin (HbA1c) remained high (mean ± SD: 12.9 ± 1.1), without any improvement of the skin lesions. In 2008 she returned to MDI, and her last HbA1c (December 2010) was 12.8%, with an increasing insulin requirement (1.58 U/kg/day). Topical steroids were unhelpful in improving skin lesions.

Open in a separate window

Figure 1

Yellow-brown, atrophic plaques surrounded by raised, violaceus rims on the right side of the lower abdomen (a); particular of the skin lesions (b).

Open in a separate window

Figure 2

Skin lesions typically appear on the legs (a); particular of the skin lesions (b).

2. Discussion

Necrobiosis lipoidica (NL) is an idiopathic dermatological condition that is strongly associated with diabetes mellitus, so much so that some authors name it “diabeticorum.”

NL is characterized by a rash that occurs on the lower legs and only rarely on hands, fingers, face, and scalp [1]. It is noteworthy that, in our patient, beyond the usual presentation on the legs, two skin lesions appeared on the lower part of the abdomen.

At the beginning, the lesions appeared as erythematous circle papules that then evolve to well-demarcated, atrophic, shiny, yellow-brown telangiectasic multiple and bilateral plaques. Except as they are ulcerated, the lesions are generally asymptomatic [2]. NL is more common in women than in men [1], and it appears usually in young or middle adulthood [3]; few cases have been, however, reported in childhood [4]. NL prevalence varies from 0.3% to 1.2% among diabetic patients [2], two-thirds of whom have type 1 diabetes.

The pathogenesis of NL is largely enigmatic. It has been suggested that NL is one of the possible manifestations of microangiopathy, due to its clear association with diabetes. Some authors [5] suggest that in patients with diabetes NL might be a warning sign for nephropathy and retinopathy. Whether or not poor glucose control is associated with the development and progression of NL lesion remains controversial [6]. Despite its possible role in NL pathogenesis, tight glycemic control might prevent NL or even improve skin lesions, when present [6].

Few data exist in pediatric population. A recent paper by Pavlović et al. [7] reported an NL incidence of 2.3%, higher than that reported in the literature; there are 5 patients (4 females and 1 male) out of 212 patients with type 1 diabetes (mean age 14 years, mean disease duration 7 years); no significant relationship has been observed with disease duration, age, glycemic control. After a review of our patients, we have found 3 patients with NL out of 240 (1.25%), 2 females and 1 male. All of them have poor glycemic control (mean HbA1c: 13.4 ± 2.1%), initial sign of microangiopathic complications (2 nephropathy, 3 neuropathy, 1 retinopathy). However, glycemic control per se is not suggestive of NL appearance. Indeed, in our population only 3 patients out of the about 30 with a steady HbA1c value above 9% developed NL, confirming that other factors have to be involved in NL pathogenesis. The finding of IgM, IgG, IgA, and C3 in blood vessel walls might support the role of immunological-mediated vascular disease in NL.

Some authors [8] regard NL to be a primary disease of collagen, with inflammation occurring as a second event. For this reason a strict avoidance of trauma is suggested to prevent ulceration and the development of new lesions.

NL diagnosis is commonly a clinical one; only in those few cases, usually in the starting stages of the disease, when the diagnosis may be awkward, a biopsy of the lesion can be useful.

Treatment of NL is often difficult. First-line therapies include smoking cessation and diabetes control improvement. In addition, topical and intralesional corticosteroid may be effective [9], even if they can increase glycemic values. In the present case, no improvement of the skin lesions has been observed despite the use of topical corticosteroid. A possible explanation could be the steady bad glycemic control of the patient.

Recently, a new therapeutic attempt has been reported, including topical PUVA photochemotherapy [10]: after a mean of 47 sessions all 10 treated patients experienced almost complete remission of the skin lesions.

On the other side, systemic therapies using corticosteroids and azathioprine could facilitate malignant transformation [11]. Squamous cell carcinomas have been reported to arise in areas of NL [11].

Differential diagnosis includes granuloma annulare, sarcoidosis, and amyloidosis. Granuloma annulare has typical lesions with epidermis not thinned. Besides the histopathologic findings that may rule out the differences between the diseases, it shows resolution with near restoration of structure, normal and without sclerosis. On the other hand, necrobiosis lipoidica shows a progression to collagen bundles in the reticular dermis in septa in the subcutaneous fat becoming crowded and thickened. Sarcoidosis is a multisystem disease that may involve almost any organ system, and its dermatological findings can assume a vast array of morphologies. Correctly diagnosing sarcoidosis may be a challenge. Patients are diagnosed with sarcoidosis when a compatible clinical or radiologic picture is present, along with histologic evidence of noncaseating granulomas, and when other potential causes, such as infections, are excluded. Amyloidosis is a systemic disease too, a plasma-cell dyscrasia of unknown cause, with well-recognized dermatological signs that may be the presenting features. Skin and soft-tissue lesions may, indeed, be the only manifestations of the disease prior to later-stage organ involvement. Although the skin manifestations of systemic amyloid are common to many conditions, their presentation in certain clinical settings should help to indicate this disorder for inclusion in the differential diagnosis.

Disclosure

None of the authors have any financial interest related to the study to disclose.

References

1. Bello YM, Phillips TJ. Necrobiosis lipoidica: indolent plaques may signal diabetes. Postgraduate Medicine. 2001;109(3):93–94. [PubMed] [Google Scholar]

2. Ahmed I, Goldstein B. Diabetes mellitus. Clinics in Dermatology. 2006;24(4):237–246. [PubMed] [Google Scholar]

3. O’Toole EA, Kennedy U, Nolan JJ, Young MM, Rogers S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. British Journal of Dermatology. 1999;140(2):283–286. [PubMed] [Google Scholar]

4. De Silva BD, Schofield OM, Walker JD. The prevalence of necrobiosis lipoidica diabeticorum in children with type 1 diabetes. British Journal of Dermatology. 1999;141(3):593–594. [PubMed] [Google Scholar]

5. Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease. Pediatric Dermatology. 1995;12(3):220–223. [PubMed] [Google Scholar]

6. Cohen O, Yaniv R, Karasik A, Trau H. Necrobiosis lipoidica and diabetic control revisited. Medical Hypotheses. 1996;46(4):348–350. [PubMed] [Google Scholar]

7. Pavlović MD, Milenković T, Dinić M, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care. 2007;30(8):1964–1967. [PubMed] [Google Scholar]

8. Lowitt MH, Dover JS. Necrobiosis lipoidica. Journal of the American Academy of Dermatology. 1991;25(5 I):735–748. [PubMed] [Google Scholar]

9. Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking, and proteinuria. A case controlled study. Diabetic Medicine. 1993;10(8):725–728. [PubMed] [Google Scholar]

10. Narbutt J, Torzecka JD, Sysa-Jedrzejowska A, Zalewska A. Long-term results of topical PUVA in necrobiosis lipoidica. Clinical and Experimental Dermatology. 2006;31(1):65–67. [PubMed] [Google Scholar]

11. Gudi VS, Campbell S, Gould DJ, Marshall R. Squamous cell carcinoma in an area of necrobiosis lipoidica diabeticorum: a case report. Clinical and Experimental Dermatology. 2000;25(8):597–599. [PubMed] [Google Scholar]

Articles from Case Reports in Pediatrics are provided here courtesy of Hindawi Limited

Necrobiosis Lipoidica Diabeticorum (2024)

FAQs

Necrobiosis Lipoidica Diabeticorum? ›

Necrobiosis lipoidica diabeticorum is an uncommon skin condition related to diabetes . It results in reddish brown areas of the skin, most commonly on the lower legs.

How do you get rid of Necrobiosis Lipoidica Diabeticorum? ›

Cyclosporine at doses of 2.5 mg/kg/day has also been used with success in treating ulcerated necrobiosis lipoidica. A study by Ginocchio et al also indicated that topical tacrolimus is effective, as demonstrated in the case of a nondiabetic woman aged 55 years with refractory ulcerated necrobiosis lipoidica.

What is necrobiosis Lipoidica diabeticorum HCC? ›

Necrobiosis lipoidica diabeticorum ("NLD") is a rash that occurs on the lower legs. It is more common in women, and there are usually several spots. They are slightly raised shiny red-brown patches. The centers are often yellowish and may develop open sores that are slow to heal.

What is the first line treatment for necrobiosis lipoidica? ›

First-line management usually includes topical or intralesional corticosteroids, though NL is commonly refractory to treatment, requiring multimodal therapy. Although numerous other treatments have been reported as efficacious, the majority of these are in case reports.

Can you have necrobiosis Lipoidica diabeticorum without diabetes? ›

Although the name implies diabetes and the majority of cases occur in diabetics, this condition can occur in individuals without diabetes. Necrobiosis lipoidica diabeticorum is a chronic skin disease characterized by shiny plaques that vary in color from light yellowish to reddish-tan.

Does necrobiosis lipoidica go away? ›

NLD is a long-term disease. Lesions do not heal well and can recur. Ulcers are difficult to treat. The appearance of the skin may take a long time to become normal, even after treatment.

What cream is good for necrobiosis lipoidica? ›

Ruxolitinib Cream in the Treatment Cutaneous Necrobiosis Lipoidica - Mayo Clinic.

Does necrobiosis Lipoidica Diabeticorum go away? ›

Photodynamic therapy has also been suggested for photorejuvenation of UV-light damaged skin. Necrobiosis lipoidica diabeticorum may undergo spontaneous remission with or without residual cutaneous atrophy and scarring, which develops over a longer period.

What is the prognosis for Necrobiosis Lipoidica diabeticorum? ›

The disease is typically chronic with variable progression and scarring. Squamous cell cancers have been reported in older lesions of necrobiosis lipoidica related to previous trauma and ulceration. From a cosmetic standpoint, the prognosis of necrobiosis lipoidica is poor.

Is necrobiosis lipoidica serious? ›

Although the condition itself is harmless, complications such as infection or scarring can sometimes occur. A doctor will examine the site and ask about any underlying health conditions to help diagnose NL. If they are in any doubt, the doctor may take a small sample (biopsy) of the affected tissue for testing.

What are the cures for necrobiosis lipoidica? ›

The following treatments have helped some patients: Injections of steroid into the inflamed parts of necrobiosis lipoidica can be very helpful (see Patient Information Leaflet on Intralesional Steroid Therapy). Strong steroid creams or ointments, sometimes covered by a plastic film, may help areas that are spreading.

What is the cause of Necrobiosis Lipoidica Diabeticorum? ›

The cause of necrobiosis lipoidica diabeticorum (NLD) is unknown. It is thought to be linked to blood vessel inflammation related to autoimmune factors. This damages proteins in the skin (collagen). People with type 1 diabetes are more likely to get NLD than those with type 2 diabetes.

What are the complications of Necrobiosis Lipoidica diabeticorum? ›

What are the complications of necrobiosis lipoidica? Ulceration complicates 1/3 of cases of necrobiosis lipoidica, usually following minor injury to an established patch. The ulcer may be very painful or painless. Ulcers due to necrobiosis lipoidica are at risk of secondary bacterial infection and delayed healing.

What is another name for Necrobiosis Lipoidica diabeticorum? ›

Necrobiosis lipoidica was first mentioned as dermatitis atrophicans lipoidica diabetica in 1929 by Oppenheim. However, in 1932, Urbach renamed the disease necrobiosis lipoidica diabeticorum (NLD).

What is the most common site of necrobiosis lipoidica? ›

The legs are the most common site for NLD, but involvement of other areas such as the abdomen, upper extremities and scalp has been reported. There is no rational therapy.

Is necrobiosis Lipoidica Diabeticorum painful? ›

The ulcers run a refractory course and usually are resistant to treatment. The ulcers in NL are quite painful leading to impaired quality of life of these patients.

Does necrobiosis lipoidica diabeticorum go away? ›

Photodynamic therapy has also been suggested for photorejuvenation of UV-light damaged skin. Necrobiosis lipoidica diabeticorum may undergo spontaneous remission with or without residual cutaneous atrophy and scarring, which develops over a longer period.

Top Articles
Latest Posts
Article information

Author: Delena Feil

Last Updated:

Views: 6001

Rating: 4.4 / 5 (65 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Delena Feil

Birthday: 1998-08-29

Address: 747 Lubowitz Run, Sidmouth, HI 90646-5543

Phone: +99513241752844

Job: Design Supervisor

Hobby: Digital arts, Lacemaking, Air sports, Running, Scouting, Shooting, Puzzles

Introduction: My name is Delena Feil, I am a clean, splendid, calm, fancy, jolly, bright, faithful person who loves writing and wants to share my knowledge and understanding with you.